Research Paper Volume 14, Issue 6 pp 2868—2879

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types


Figure 2. Associations of TP53 and BRAF mutation types with prognosis in patients treated with immune checkpoint inhibitors. (A) Patients with the BRAF mutation alone had the best prognosis, while patients with TP53 mutation alone had the worst prognosis. Patients with mutations in both or none had median survival. (B) Patients in high-TMB status group had longer OS than patients in low-TMB status group. (C, D) In both high-TMB/low-TMB status groups, TP53MUTBRAFWT indicated poorer OS, while BRAFMUTTP53WT did the opposite. BRAF indicates B-Raf Proto-Oncogene, Serine/Threonine Kinase gene; TP53 indicates tumor protein p53 gene; MUT indicates mutant genes; WT indicates wild type genes; TMB indicates tumor mutation burden; MSI indicates microsatellite instable.